Enovis (ENOV) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
13 May, 2026Executive summary
Q1 2026 net sales reached $589 million, up 5% reported and 3% organic year-over-year, driven by strong execution, innovation, and new product launches in both business segments.
Adjusted gross margin expanded to 62.1%, up 250–260 bps year-over-year, with improved product mix and operational efficiency despite tariff headwinds.
Adjusted EBITDA was $104 million (17.6% margin), up from $87 million, and adjusted EPS rose to $0.89, a 10% year-over-year increase.
Net loss narrowed significantly to $8.5 million from $55.7 million, with adjusted net income at $51.6 million (8.8% margin).
Leadership and operating model changes, along with strategic product launches, supported above-market growth and improved management rigor.
Financial highlights
Net sales for Q1 2026 were $589.2 million, up from $558.8 million year-over-year.
Adjusted gross profit was $366 million (62.1% margin), up from $333 million (59.6% margin) in Q1 2025.
Adjusted EBITDA reached $104 million (17.6% margin), compared to $87 million (15.6% margin) in Q1 2025.
Adjusted net income was $51.6 million, with adjusted net income margin at 8.8%.
Free cash flow improved by $16 million year-over-year.
Outlook and guidance
Full-year 2026 revenue guidance reaffirmed at $2.31–$2.37 billion, with 4–6% organic growth expected.
Adjusted EBITDA guidance maintained at $425–$435 million; adjusted EPS expected in the range of $3.52–$3.73.
Free cash flow conversion expected to exceed 25% for 2026.
Guidance incorporates headwinds from Middle East revenue exposure, supply chain inflation, and tariff impacts of ~$15 million.
Margin cadence and EPS growth anticipated to improve in the second half of 2026.
Latest events from Enovis
- Virtual annual meeting to vote on directors, auditor, compensation, and incentive plan.ENOV
Proxy filing6 Apr 2026 - Board recommends all proposals, emphasizing governance, pay-for-performance, and ESG focus.ENOV
Proxy filing6 Apr 2026 - Double-digit growth, tech innovation, and ASC expansion fuel strong outlook for 2026.ENOV
2026 CG Musculoskeletal Conference4 Mar 2026 - 2025 saw robust sales growth, margin gains, and innovation, with 2026 guidance targeting further improvements.ENOV
Q4 202526 Feb 2026 - Lima integration and new product launches drive growth, margin expansion, and innovation in 2025.ENOV
CG 2025 Musculoskeletal Conference13 Feb 2026 - Q2 sales up 23%, margin expansion, and Lima integration ahead of plan with raised EPS guidance.ENOV
Q2 20242 Feb 2026 - Integration and portfolio expansion drive growth, margin gains, and strong outlook into 2025.ENOV
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Lima acquisition and innovation drive 2024 growth, margin gains, and integration progress.ENOV
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - 2024 growth guided at 5%-6% with margin expansion as integration headwinds ease.ENOV
2024 Wells Fargo Healthcare Conference22 Jan 2026